KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $114,000.

  • Nektar Therapeutics' Capital Expenditures fell 82.88% to $114,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $612,000, marking a year-over-year decrease of 50.88%. This contributed to the annual value of $1.5 million for FY2024, which is 69.71% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Capital Expenditures is $114,000, which was up 208.11% from $37,000 recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Capital Expenditures ranged from a high of $5.9 million in Q4 2021 and a low of $2,000 during Q1 2025.
  • Its 3-year average for Capital Expenditures is $226,000, with a median of $162,000 in 2023.
  • In the last 5 years, Nektar Therapeutics' Capital Expenditures surged by 1,918.18% in 2024 and then crashed by 98.73% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Capital Expenditures (Quarterly) stood at $5.9 million in 2021, then plummeted by 91.32% to $512,000 in 2022, then tumbled by 53.71% to $237,000 in 2023, then surged by 93.67% to $459,000 in 2024, then slumped by 82.88% to $114,000 in 2025.
  • Its Capital Expenditures was $114,000 in Q3 2025, compared to $37,000 in Q2 2025 and $2,000 in Q1 2025.